Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire - Wed Oct 18, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 13.56 (-1.31%)
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada PR Newswire - Tue Sep 19, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 13.56 (-1.31%)
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a...

INBX : 13.56 (-1.31%)
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire - Mon May 8, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong...

INBX : 13.56 (-1.31%)
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results PR Newswire - Mon Mar 6, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong...

INBX : 13.56 (-1.31%)
NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates PR Newswire - Wed Jan 4, 2023

/PRNewswire/ -- NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for...

INBX : 13.56 (-1.31%)
NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates Business Wire - Wed Jan 4, 2023

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Inhibrx,...

INBX : 13.56 (-1.31%)
Inhibrx Announces Participation in Upcoming Investor Conference PR Newswire - Fri Nov 18, 2022

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 13.56 (-1.31%)
Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights PR Newswire - Mon Nov 7, 2022

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today...

INBX : 13.56 (-1.31%)
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire - Thu Oct 20, 2022

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 13.56 (-1.31%)

Barchart Exclusives

3 Top-Rated Dividend Kings Trading Near Their 52-Week Lows Barchart - 17 minutes ago
These quality companies all have something in common: They are trading a little off their 52-week lows and pay an ever-increasing dividend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot